Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim International Gmbh

Volastra Therapeutics, Inc.

Boehringer Ingelheim Pharma Gmbh & Co Kg

Derek Cogan

Ming-Hong Hao

Zhaoming Xiong

Matthew Russell Netherton

Craig Andrew Miller

Daniel R Goldberg

Alan David Swinamer

Zhidong Chen

Donghong Amy Gao

Daniel Richard Marshall

Alexander Heim-Riether

Bryan Patrick McKibben

Ronald A Aungst, Jr

Jennifer Burke

Philip Dean Ramsden

Neil Moss

Yunlong Zhang

John Lord

Xin Guo

Michael Balestra

Kenneth Michael Meyers

Roger John Snow

Sarah Bettigole

Lee Fader

Lana Louise Smith Keenan

Maolin Yu

Victor Marc Kamhi

Kevin Chungeng Qian

Hui Yu

Yang Yu

Piotr Nieczypor

Leon Van Berkom

Michael Su

Eugene R Hickey

Weimin Liu

Denice Mary Spero

Mario G Cardozo

Rene Marc Lemieux

Christopher Ronald Sarko

Erick Richard Roush Young

Zhonghua Zhang

Heather Tye

Abdelhakim Hammach

Keith R Hornberger

Charles Lawrence Cywin

Mark Whittaker

Michael Jason Burke

Peter Allen Nemoto

Pui Leng Loke

John David Ginn

Jiang-Ping Wu

Steven Richard Brunette

Matt Aaron Tschantz

Asitha Abeywardane

Wang Mao

Darren DiSalvo

Joerg Bentzien

Jennifer A Kowalski

Jörg Martin Bentzien

Joshua Courtney Horan

David Charles Thompson

Kenneth M Meyers

Amy L Davis

Michael David Lawlor

Simon Suprenant

Yu Yang

Antonio Jose Del Moral Barbosa, Jr

Anthony S Prokopowicz, Iii

Matthew A Cerny

Kosea S Frederick

Rutger Folmer

Prashanna Vijayachandran

Gydo Van Der Heijden

Samantha Jayne Bamford

Younggi Choi

George Dahmann

Jörg Bentzien

Bryan P Mckibben

Simon Surprenant

Alan D Swinamer

Ronald A Aungst

Joerg Martin Bentzien

Bryan Mckibben

Donghong A Gao

Antonio Jose Del Moral Barbosa

Criag Andrew Miller

The present disclosure relates generally to inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to triazolopyrimidine and imidazolopyrimidine inhibitors of ENPP1 and methods of their use for treating disease mediated by ENPP1.

Heterocyclic inhibitors of ENPP1

The present disclosure relates generally to inhibitors of KIF18A, compositions thereof, and methods of using the compounds and compositions thereof. More specifically, the present disclosure relates to indoline inhibitors of KIF18A and methods of their use for treating disease mediated by KIF18A, such as cancer.

Indoline compounds for inhibiting KIF18A

The present disclosure relates generally to inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to sulfoximine-based inhibitors of ENPP1 and methods of their use for treating disease mediated by ENPP1.

Imino sulfanone inhibitors of ENPP1

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R, R, R, R, Rand n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. 

Bicyclic imidazole derivatives useful for the treatment of renal diseases, cardiovascular diseases and fibrotic diseases

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein X, R, Rand Rare as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. 

Aldosterone synthase inhibitors

The present invention relates to compounds of the formulas (IA) and (IB) and pharmaceutically acceptable salts thereof, wherein A and R-R, are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. 

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein Cy, Rand Rare as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, R, R, W, Y, m and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Disclosed is a compound of formula (I). Wherein R, RAr and Cy are as defined herein, or a pharmaceutically acceptable salt thereof. Also disclosed are pharmaceutical compositions of the compound of formula (I), methods of making the compounds of formula I, and methods of using the compounds of formula (I) to treat a disorder associated with activation of CCR10. 

[object Object]

Disclosed are Cathepsin-S reversible inhibitor compounds of the formula (I) which are useful in the treatment of autoimmune and other diseases. Also disclosed are pharmaceutical compositions containing the same, and methods of making and using the same. 

Heteroaryl nitrile compounds useful as inhibitors of Cathepsin-S

Disclosed are Serotonin 5-HT2B receptor inhibitors of the formula I. Also disclosed are methods of making and methods of using these compounds. 

Serotonin 5-HT2B receptor inhibitors

This invention relates to a compound of formula (I) and the pharmaceutically acceptable salts thereof wherein R, R, R. Ar and Het are as defined herein. The invention also relates to methods of using the compound of formula (I) to treat a diseases and disorders that are mediated or sustained through the activity of CCR10. 

2-sulfonylamino-4-heteroaryl butyramide antagonists of CCR10

Derivatives of 6,7-dihydro-5H-imidazo[1,2-&#x3b1;]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.

Derivatives of 6,7-dihydro-5H-imidazo[1,2-alpha]imidazole-3-carboxylic acid amides

The application relates to compounds of formula Ia and analogues thereof wherein Rto Rand X are as defined herein. The invention also relates to the use of the compounds of formula Ia as inhibitors of Mitogen-Activated Protein Kinase-Activated Protein kinase-2 (MAPKAP-k2), and also to a method for preventing or treating a disease or disorder that can be treated or prevented by modulating the activity of MAPKAP-K2 in a subject and to pharmaceutical compositions and kits that include these MAPKAP-K2 inhibitors.

Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors

Disclosed are compounds of formula (I) which inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.

Cytokine inhibitors

Growing community of inventors

Sandy Hook, CT, United States of America

Derek Cogan